NHS
Mersey and West Lancashire Teaching Hospitals
NHS Trust

Ref. No:	1437
Date:	07/01/25
Subject:	Fibrinogen Concentrate, Prothrombin Complex Concentrate, DOAC Antidote, and blood products

REQUEST

I would like to submit an FOI request for the number of **vials used** and **patients treated** for the following products at your trust used in 2024 (total January to December), broken down **by brand and size**, if possible. If the full-year data is not yet available, you can inform me about the currently available data.

If not all products are available at your institution, you can just fill in the data that you have access to.

Product	Manufacturer	Size (Units/mg)	Number of vials used (Jan 24-Dec 24)	Number of patients treated (Jan 24-Dec 24)
Prothrombin Complex Concentrate (PCC)				
Beriplex	CSL Behring	500IU 20ml		
		1000IU 40ml		
Octaplex	Octapharma	500IU 20ml		
		1000IU 40ml		
Prothromplex	Takeda	600IU 17ml		
FEIBA	Takeda	200IU 10ml		
		500IU 20ml		
		1000IU 40ml		
Others (if any please specify)		(if any please		

		specify)		
Reversal Agents				
Ondexxya (andexanet alfa)	Astrazeneca	5x 200 mg	25	
Praxbind (Idaracizumab)	Boehringer Ingelheim	2x 2.5 g	<5	
Fibrinogen Concentrate (FC)				
RiaSTAP	CSL Behring	1.0g		
FibCLOT	LFB	1.5g		
Fibryga	Octapharma	1.0g	71	
Others (if any please specify)		(if any please specify)		
Fresh Frozen Plasma (FFP)				
Fresh Frozen Plasma	Blood banks			
Octaplas	Octapharma			
Cryoprecipitate				
Cryoprecipitate	Blood banks			
Labile Blood Products				
Whole blood	Blood banks			
Red blood cells	Blood banks			
Platelets	Blood banks			
Factor XIII				
Fibrogammin	CSL Behring	250IU 4ml 1250IU 20ml		

<5

Due to the low number of patients receiving the some of the above medications which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.